ReviewOncology reports2026
Sterol regulatory element‑binding proteins: Master regulators of lipid metabolic reprogramming in cancer and emerging therapeutic targets (Review).
Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sterol regulatory element‑binding proteins (SREBPs) are key regulatory factors of lipid synthesis. Tumor cells are highly dependent on SREBP‑driven lipid synthesis for the biogenesis of their cell membranes and signaling molecules. The aberrant activation of SREBPs is a critical event that drives tumorigenesis and progression. SREBPs are a subset of membrane‑bound proteins that function as basic helix‑loop‑helix leucine zipper (bHLH‑Zip) transcription factors. They mainly maintain the homeostasis of lipid metabolism in the body by activating the genes related to the synthesis and uptake of cholesterol, fatty acids and triglycerides. In addition to their involvement in tumor lipid metabolic reprogramming, SREBPs play critical roles in obesity, atherosclerosis, diabetes mellitus and neurodegenerative diseases. The present review summarizes the regulatory mechanisms of SREBPs, their aberrant activation in tumors, their role in promoting the malignant progression of tumors, as well as the relevant targeted therapeutic strategies from different aspects. In conclusion, targeting SREBPs is a promising anticancer strategy, and future studies are needed to further elucidate their intricate regulatory networks to advance precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.